Recently, zenocutuzumab was approved for the treatment of adult patients with advanced unresectable or metastatic non-small cell lung or pancreatic cancer who are positive for NRG1 fusion and who have experienced disease progression despite other treatments. Here, NRG1 is linked to pancreatic neoplasm.